Director · Zentalis Pharmaceuticals, Inc. · Common Stock
Side
A
Value
—
Shares
57.1K
Price
—
Executed
Jun 16, 2026
Disclosed
Jun 18, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Jun 16 executedJun 18, 2026 disclosed
ZNTL · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Grant or award — administrative, little informational value
Relative size+9 / 25
No reported dollar value · 27.6% of prior position
Filing timing0 / 15
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Skvarka Jan filed this Form 4 reporting a grant or award of ZNTL on Jun 16, 2026. It became public on Jun 18, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director
Skvarka Jancik:0001838042
Issuer
Zentalis Pharmaceuticals, Inc.cik:0001725160
Revision history · 0
No field has changed since this record was first ingested.
